Iara Sofía Santa Cruz

Ms. Iara Sofía Santa Cruz


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in British Journal of Radiology
Verified
Journal Article
Closed access
VTVerónica Andrea Trivillin
Verónica Andrea Trivillin
YLYanina V. Langle
Yanina V. Langle
MPMónica Alejandra Palmieri
Mónica Alejandra Palmieri
EPEmiliano C.C. Pozzi
Emiliano C.C. Pozzi
STSilvia I. Thorp
Silvia I. Thorp
Amanda SchwintAmanda Schwint
Amanda Schwint
We previously demonstrated, for the first time, the abscopal effect of Boron Neutron Capture Therapy (BNCT) in an ectopic model of syngeneic colon cancer in BDIX rats. Objective: The aim of the present study was to evaluate the local and regional therapeutic efficacy and abscopal effect of BNCT mediated by boronophenyl-alanine, combined with Bacillus Calmette-Guerin (BCG) as an immunotherapy agent in this model. Methods: The local effect of treatment was evaluated in terms of tumor response in the irradiated tumor-bearing right hind flank. Metastatic spread to tumor-draining lymph nodes was analyzed as an indicator of regional effect. The abscopal effect of treatment was assessed as tumor growth inhibition in the contralateral (non-irradiated) left hind flank inoculated with tumor cells 2 weeks post-irradiation. The experimental groups BNCT, BNCT + BCG, BCG, Beam only (BO), BO +BCG, SHAM (tumor-bearing, no treatment, same manipulation) were studied. Results: BNCT and BNCT + BCG induced a highly significant local anti-tumor response, whereas BCG alone induced a weak local effect. BCG and BNCT + BCG induced a significant abscopal effect in the contralateral non-irradiated leg. The BNCT + BCG group showed significantly less metastatic spread to tumor-draining lymph nodes vs SHAM and vs BO. Conclusion: This study suggests that BNCT + BCG-immunotherapy would induce local, regional and abscopal effects in tumor-bearing animals. BNCT would be the main effector of the local anti-tumor effect whereas BCG would be the main effector of the abscopal effect. Advances in knowledge: Although the local effect of BNCT has been widely evidenced, this is the first study to show the local, regional and abscopal effects of BNCT combined with immunotherapy, contributing to comprehensive cancer treatment with combined therapies.

7 October 2020 in Biology
Verified
Journal Article
Open access
PDF file
Amanda SchwintAmanda Schwint
Amanda Schwint
Andrea Monti HughesAndrea Monti Hughes
Andrea Monti Hughes
MGMarcela Alejandra Garabalino
Marcela Alejandra Garabalino
GCGustavo A. Santa Cruz
Gustavo A. Santa Cruz
SGSara J. González
Sara J. González
Iara Sofía Santa CruzIara Sofía Santa Cruz
Iara Sofía Santa Cruz
Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.

20 July 2022 in Life
Verified
Journal Article
Open access
PDF file
Andrea Monti HughesAndrea Monti Hughes
Andrea Monti Hughes
JGJessica A. Goldfinger
Jessica A. Goldfinger
MPMónica Alejandra Palmieri
Mónica Alejandra Palmieri
PRPaula Ramos
Paula Ramos
Iara Sofía Santa CruzIara Sofía Santa Cruz
Iara Sofía Santa Cruz
Amanda SchwintAmanda Schwint
Amanda Schwint
Background: BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although p-boronophenylalanine (BPA) has been clinically used, new boron compounds are needed for the advancement of BNCT. Based on previous studies in colon tumor-bearing mice, in this study, we evaluated MID:BSA (maleimide-functionalized closo-dodecaborate conjugated to bovine serum albumin) biodistribution and MID:BSA/BNCT therapeutic effect on tumors and associated radiotoxicity in the hamster cheek pouch oral cancer model. Methods: Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. Results: MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. Conclusions: MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.

27 May 2019
Verified
Conference Paper
Closed access
GCGustavo Santa Cruz
Gustavo Santa Cruz
SGSara Gonzalez
Sara Gonzalez
APAgustina Mariana Portu
Agustina Mariana Portu
Amanda SchwintAmanda Schwint
Amanda Schwint
MGMarcela Alejandra Garabalino
Marcela Alejandra Garabalino
GBGuillermo Belerenian
Guillermo Belerenian
As part of the Boron Neutron Capture Therapy (BNCT) project conducted by the Argentine National Atomic Energy Commission (CNEA), Dynamic Infrared |

28 May 2019
Verified
Conference Paper
Closed access
VTVerónica Andrea Trivillin
Verónica Andrea Trivillin
PRPaula Ramos
Paula Ramos
Iara Sofía Santa CruzIara Sofía Santa Cruz
Iara Sofía Santa Cruz
APAgustina Mariana Portu
Agustina Mariana Portu
GMGisela Saint Martin
Gisela Saint Martin
Amanda SchwintAmanda Schwint
Amanda Schwint
Introduction: A critical aspect of the therapeutic efficacy of BNCT is the biodistribution of 10B in tumor and in the dose limiting normal and pr |

28 May 2019
Verified
Conference Paper
Open access
Andrea Monti HughesAndrea Monti Hughes
Andrea Monti Hughes
JGJessica A Goldfinger
Jessica A Goldfinger
VTVerónica Andrea Trivillin
Verónica Andrea Trivillin
MPMónica Alejandra Palmieri
Mónica Alejandra Palmieri
MGMarcela Alejandra Garabalino
Marcela Alejandra Garabalino
Amanda SchwintAmanda Schwint
Amanda Schwint
Introduction Unresectable head and neck tumors are treated with radiation therapy or chemoradiotherapy, but the dose that can be administered to |